Halozyme Therapeutics, Inc. (HALO)

NASDAQ: HALO · Real-Time Price · USD

108.17

+2.05 (1.93%)

At close: Aug 21, 2026, 4:00 PM EDT

108.40

+0.23 (0.21%)

After-hours: Aug 21, 2026, 7:20 PM EDT

Halozyme Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	163.14	133.82	115.85	118.37	234.2	118.72
Short-Term Investments	67.87	9	480.22	217.63	128.6	622.2
Cash & Short-Term Investments	231	142.82	596.07	336	362.79	740.92
Cash Growth	-57.86%	-76.04%	77.40%	-7.38%	-51.03%	101.33%
Accounts Receivable	455.83	439.66	308.46	234.21	231.07	90.98
Other Receivables	-	1.61	-	-	-	-
Receivables	455.83	441.27	308.46	234.21	231.07	90.98
Inventory	137.14	176.48	141.86	127.6	100.12	53.91
Prepaid Expenses	108.26	64.64	38.95	48.61	45.02	40.48
Total Current Assets	933.02	825.21	1,085	746.42	739.01	926.29
Property, Plant & Equipment	84.27	82.14	75.04	74.94	75.57	8.79
Goodwill	581.73	580.36	416.82	416.82	409.05	-
Other Intangible Assets	922.44	981.47	401.83	472.88	546.65	-
Long-Term Deferred Tax Assets	-	-	3.86	4.39	44.43	155.43
Other Long-Term Assets	55.94	56.15	80.6	17.82	26.8	13.91
Total Assets	2,577	2,525	2,063	1,733	1,842	1,104

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	23.61	20.9	10.25	11.82	17.69	1.54
Accrued Expenses	111.86	144.92	128.85	100.68	97.66	22.17
Current Portion of Long-Term Debt	208.97	-	-	-	13.33	89.42
Current Portion of Leases	-	11.28	-	-	2.1	2.28
Current Unearned Revenue	-	-	-	-	-	1.75
Total Current Liabilities	344.44	177.09	139.1	112.49	130.79	117.15
Long-Term Debt	1,938	2,143	1,506	1,499	1,493	787.26
Long-Term Leases	31.88	23.29	-	32.2	32.69	0.54
Long-Term Unearned Revenue	-	-	-	-	-	2.53
Long-Term Deferred Tax Liabilities	49.06	42.92	-	-	-	-
Other Long-Term Liabilities	70.8	90.57	54.76	5.52	15.47	-
Total Liabilities	2,434	2,477	1,700	1,649	1,672	907.48

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.11	0.12	0.12	0.13	0.14	0.14
Additional Paid-In Capital	-	12	-	2.41	27.37	256.35
Retained Earnings	151.26	54.79	359.87	90.55	143.22	-58.91
Comprehensive Income & Other	-7.83	-18.09	3.83	-9.28	-0.92	-0.62
Shareholders' Equity	143.54	48.81	363.82	83.81	169.8	196.95
Total Liabilities & Equity	2,577	2,525	2,063	1,733	1,842	1,104

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	2,179	2,177	1,506	1,531	1,541	879.49
Net Cash (Debt)	-1,948	-2,034	-909.72	-1,195	-1,178	-138.57
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-15.93	-16.42	-7.03	-8.91	-8.38	-0.94
Filing Date Shares Outstanding	113.5	118.02	123.15	126.82	135.37	137.7
Total Common Shares Outstanding	114.04	117.78	123.14	126.77	135.15	137.5
Working Capital	588.59	648.12	946.24	633.93	608.22	809.14
Book Value Per Share	1.26	0.41	2.95	0.66	1.26	1.43
Tangible Book Value	-1,361	-1,513	-454.83	-805.89	-785.9	196.95
Tangible Book Value Per Share	-11.93	-12.85	-3.69	-6.36	-5.81	1.43
Machinery	73.62	68.2	57.53	50.78	43.13	18.26
Leasehold Improvements	7.52	7.52	7.01	6.99	6.73	1.63
Order Backlog	-	289.5	-	-	-	-

SEC Filings: 10-K · 10-Q